How to Navigate Ecosystem Connect NEW Distinguished Investigators 
Global Conferences RLT Education RLT Components Sponsors Trial Stats
Global Conferences RLT Education RLT Components Sponsors Trial Stats 
How to NavigateNEW Ecosystem Connect Distinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats Dictionary About Us Our Values
Contact XCancer
Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.comEvaluation of 68Ga-DOTATOC PET/CT-enterography for the Detection of the Primary Lesion in Neuroendocrine Tumors of the Small Bowel
Description:
The aim of this study is to calculate the sensitivity (SE), the specificity (SP), the positive and negative predictive values (PPV and NPV) and the overall accuracy of 68Ga-DOTATOC PET/CT-enterography in detecting in primary lesion and multifocality of siNETs.
Sponsor:
European Institute of OncologyPhase:
N/A
Contacts:
Luigi Funicelli, MDluigi.funicelli@ieo.it
+390294372725
Government Study Link:
NCT06773624 - Click here to see study onClinicalTrials.gov
68Ga-DOTATOC
Isotope(s):
GALLIUM-68
Radioisotope: Ga-68
Theranostic Role: PET Imaging
T1/2 (Half-Life): 68 minutes
Decay Mode: POSITRON β+ (88.9%), GAMMA, ELECTRON CAPTURE (8.7%)
Energy: Beta: max 1.9 MeV Gamma 1.1 MeV, 511 keV
Range: N/A
Decay Daughters: Zn68 (Stable)
Status: FDA Approvals: NETSPOT® (2016), LOCAMETZ® (2022), ILLUCIX® (2021)
Target(s):
- SSTR+
Linker: Dotatate
Share your feedback
Help us improve your experience